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Summary
Schizophrenia is a highly heritable disorder. Genetic risk is conferred by a large number of alleles,
including common alleles of small effect that might be detected by genome-wide association
studies. Here, we report a multi-stage schizophrenia genome-wide association study of up to
36,989 cases and 113,075 controls. We identify 128 independent associations spanning 108
conservatively defined loci that meet genome-wide significance, 83 of which have not been
previously reported. Associations were enriched among genes expressed in brain providing
biological plausibility for the findings. Many findings have the potential to provide entirely novel
insights into aetiology, but associations at DRD2 and multiple genes involved in glutamatergic
neurotransmission highlight molecules of known and potential therapeutic relevance to
schizophrenia, and are consistent with leading pathophysiological hypotheses. Independent of
genes expressed in brain, associations were enriched among genes expressed in tissues that play
important roles in immunity, providing support for the hypothesized link between the immune
system and schizophrenia.
Schizophrenia has a life time risk of around 1%, and is associated with substantial morbidity
and mortality as well as personal and societal costs.1-3 Although pharmacological treatments
are available for schizophrenia, their efficacy is poor for many patients.4 All available
antipsychotic drugs are thought to exert their main therapeutic effects through blockade of
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sthe type 2 dopaminergic receptor5,6 but, since the discovery of this mechanism over 60 years
ago, no new antipsychotic drug of proven efficacy has been developed based on other target
molecules. Therapeutic stasis is in large part a consequence of the fact that the
pathophysiology of schizophrenia is unknown. Identifying the causes of schizophrenia is
therefore a critical step towards improving treatments and outcomes for those with the
disorder.
High heritability points to a major role for inherited genetic variants in the aetiology of
schizophrenia. 7,8 While risk variants range in frequency from common to extremely rare9,
estimates10,11 suggest half to a third of the genetic risk of schizophrenia is indexed by
common alleles genotyped by current genome-wide association study (GWAS) arrays. Thus,
GWAS is potentially an important tool for understanding the biological underpinnings of
schizophrenia.
To date, around 30 schizophrenia-associated loci10-23 have been identified through GWAS.
Postulating that sample size is one of the most important limiting factors in applying GWAS
to schizophrenia, we created the Schizophrenia Working Group of the Psychiatric Genomics
Consortium (PGC). Our primary aim was to combine all available schizophrenia samples
with published or unpublished GWAS genotypes into a single, systematic analysis.24 Here,
we report the results of that analysis, including at least 108 independent genomic loci that
exceed genome-wide significance. Some of the findings support leading pathophysiological
hypotheses of schizophrenia or targets of therapeutic relevance, but most of the findings
provide novel insights.
128 Independent Associated Loci
We obtained genome-wide genotype data from which we constructed 49 ancestry matched,
non-overlapping case-control samples (46 of European and three of East Asian ancestry,
34,241 cases and 45,604 controls) and 3 family-based samples of European ancestry (1,235
parent affected-offspring trios) (Supplementary Table 1 and Supplementary text). These
comprise the primary PGC GWAS dataset. Genotypes from all studies were processed by
the PGC using unified quality control procedures followed by imputation of SNPs and
insertion-deletions using the 1000 Genomes Project reference panel.25 In each sample,
association testing was conducted using imputed marker dosages and principal components
(PCs) to control for population stratification. The results were combined using an inverse-
weighted fixed effects model.26 After quality control (imputation INFO score ≥ 0.6, MAF ≥
0.01, and successfully imputed in ≥ 20 samples), we considered around 9.5 million variants.
The results are summarized in Figure 1. To enable acquisition of large samples, some groups
ascertained cases via clinician diagnosis rather than a research-based assessment and
provided evidence of the validity of this approach (Supplementary text).11,13 Post-hoc
analyses revealed the pattern of effect sizes for associated loci was similar across different
assessment methods and modes of ascertainment (Extended Data Figure 1), supporting our a
priori decision to include samples of this nature.
For the subset of LD (linkage disequilibrium)-independent SNPs with P < 1×10−6 in the
meta-analysis, we next obtained results from deCODE genetics (1,513 cases and 66,236
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scontrols of European ancestry). We define LD-independent SNPs as those with low LD (r2 <
0.1) to a more significantly associated SNP within a 500 kb window. Given high LD in the
extended MHC region spans ~8 Mb, we conservatively include only a single MHC SNP to
represent this locus. The deCODE data were then combined with those from the primary
GWAS to give a dataset of 36,989 cases and 113,075 controls. In this final analysis, 128
LD-independent SNPs surpassed genome-wide significance (P ≤ 5×10−8) (Supplementary
Table 2).
As in meta-analyses of other complex traits which identified large numbers of common risk
variants, 27,28 the test statistic distribution from our GWAS deviates from the null (Extended
Data Figure 2). This is consistent with the previously documented polygenic contribution to
schizophrenia. 10,11 The deviation in the test statistics from the null (λGC = 1.47, λ1000 =
1.01) is only slightly less than expected (λGC = 1.56) under a polygenic model given fully
informative genotypes, the current sample size, and the lifetime risk and heritability of
schizophrenia.29
Multiple additional lines of evidence allow us to conclude the deviation between the
observed and null distributions in our primary GWAS indicates a true polygenic
contribution to schizophrenia. First, applying a novel method 30 that uses LD information to
distinguish between the major potential sources of test statistic inflation, we found our
results are consistent with polygenic architecture but not population stratification (Extended
Data Figure 3). Second, for 78% of 263 LD-independent SNPs with P <1×10−6 in the case-
control GWAS, the risk alleles from were overrepresented in cases in the independent
samples from deCODE (P = 5.6 ×10−21). This degree of consistency between the primary
GWAS and the replication data is highly unlikely to occur by chance (P = 1×10−9). (Note
the tested alleles surpassed the P < 10−6 threshold in our GWAS before we added either the
trios or deCODE data to the meta-analysis. This trend test is therefore independent of the
primary case-control GWAS). Third, analysing the 1,235 parent-proband trios, we again
found excess transmission of the schizophrenia-associated allele at 69% of the LD-
independent SNPs with P <1×10−6 in the case-control GWAS. This is again unlikely to
occur by chance (P = 1×10−9) and additionally excludes population stratification as fully
explaining the associations that surpassed our threshold for seeking replication. Fourth, we
used the trios trend data to estimate the expected proportion of true associations at P
<1×10−6 in the discovery GWAS, allowing for the fact that half of the index SNPs are
expected to show the same allelic trend in the trios by chance, and that some true
associations will show opposite trends given the limited number of trio samples
(Supplementary Material). Given the observed trend test results, around 67% (95% CI
64%-73%) or N = 176 of the associations in the scan at P <1×10−6 are expected to be true,
and therefore the number of associations that will ultimately be validated from this set of
SNPs will be considerably more than those that now meet genome-wide significance. Taken
together, these analyses indicate that the observed deviation of test statistics from the null
primarily represents polygenic association signal, and that the considerable excess of
associations at the tail of extreme significance largely correspond to true associations.
Independently associated SNPs do not translate to well-bounded chromosomal regions.
Nevertheless, it is useful to define physical boundaries for the SNP associations to identify
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scandidate risk genes. We defined an associated locus as the physical region containing all
SNPs correlated at r2 > 0.6 with each of the 128 index SNPs. Associated loci within 250 kb
of each other were merged. This resulted in 108 physically distinct associated loci, 83 of
which have not been previously implicated in schizophrenia and therefore harbour potential
novel biological insights into disease aetiology (Supplementary Table 3; regional plots in
Supplementary Figure 1). The significant regions include all but 5 loci previously reported
as genome-wide significant in large samples (Supplementary Table 3).
Characterization of Associated Loci
Of the 108 loci, 75% include protein-coding genes (40% a single gene) and a further 8% are
within 20 kb of a gene (Supplementary Table 3). Notable associations relevant to major
hypotheses of the aetiology and treatment of schizophrenia include DRD2 (the target of all
effective antipsychotic drugs) and multiple genes (e.g. GRM3, GRIN2A, SRR, GRIA1)
involved in glutamatergic neurotransmission and synaptic plasticity. In addition,
associations at CACNA1C, CACNB2, and CACNA1I, which encode voltage-gated calcium
channel subunits, extend previous findings implicating members of this family of proteins in
schizophrenia and other psychiatric disorders. 11,13,31,32 Genes encoding calcium channels,
and proteins involved in glutamatergic neurotransmission and synaptic plasticity have been
independently implicated in schizophrenia by studies of rare genetic variation, 33-35
suggesting convergence at a broad functional level between studies of common and rare
genetic variation. We highlight in the supplementary text genes of particular interest within
associated loci with respect to current hypotheses of schizophrenia aetiology or treatment
(although we do not imply these genes are necessarily the causal elements).
For each of the schizophrenia associated loci, we identified a credible causal set of SNPs
(for definition see Supplementary text). 36 In only 10 instances (Supplementary Table 4) was
the association signal credibly attributable to a known nonsynonymous exonic
polymorphism. The apparently limited role of protein coding variants is consistent both with
exome sequencing findings 33 and with the hypothesis that most associated variants detected
by GWAS exert their effects through altering gene expression rather than protein
structure37,38 and with the observation that schizophrenia risk loci are enriched for
expression quantitative trait loci (eQTL).39
To try to identify eQTLs that could explain associations with schizophrenia, we merged the
credible causal set of SNPs defined above with eQTLs from a meta-analysis of human brain
cortex eQTL studies (N=550) and an eQTL study of peripheral venous blood (N=3754)40
(Supplementary Text). Multiple schizophrenia loci contained at least one eQTL for a gene
within 1 Mb of the locus (Supplementary Table 4). However, in only 12 instances was the
eQTL plausibly causal (two in brain, and nine in peripheral blood, one in both). This low
proportion suggests that if most risk variants are regulatory, available eQTL catalogs do not
yet provide power, cellular specificity, or developmental diversity to provide clear
mechanistic hypotheses for follow-up experiments.
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sBrain and Immunity
To further explore the regulatory nature of the schizophrenia associations, we mapped the
credible sets (N=108) of causal variants onto sequences with epigenetic markers
characteristic of active enhancers in 56 different tissues and cell lines (Supplementary Text).
Schizophrenia associations were significantly enriched at enhancers active in brain (Figure
2) but not in tissues unlikely to be relevant to schizophrenia (e.g., bone, cartilage, kidney,
and fibroblasts). Brain tissues used to define enhancers consist of heterogeneous populations
of cells. Seeking greater specificity, we contrasted genes enriched for expression in neurons
and glia using mouse ribotagged lines41. Genes with strong expression in multiple cortical
and striatal neuronal lineages were were enriched for associations, providing support for an
important neuronal pathology in schizophrenia (Extended Data Figure 4) but this is not
statistically more significant than, or exclusionary of, contributions from other lineages42.
Schizophrenia associations were also strongly enriched at enhancers that are active in tissues
with important immune functions, particularly B-lymphocyte lineages involved in acquired
immunity (CD19 and CD20 lines, Figure 2). These enrichments remain significant even
after excluding the extended MHC region and regions containing brain enhancers
(enrichment P for CD20 <10−6), demonstrating that this finding is not an artefact of
correlation between enhancer elements in different tissues and not driven by the strong and
diffuse association at the extended MHC. Epidemiological studies have long hinted at a role
for immune dysregulation in schizophrenia, the present findings provide genetic support for
this hypothesis. 43
Aiming to develop additional biological hypotheses beyond those that emerge from
inspection of the individual loci, we further undertook a limited mining of the data through
gene-set analysis. However, since there is no consensus methodology by which such
analyses should be conducted, nor an established optimal significance threshold for
including loci, we sought to be conservative, using only two of the many available
approaches44,45 and restricting analyses to genes within genome-wide significant loci.
Neither approach identified gene-sets that were significantly enriched for associations after
correction for the number of pathways tested (Supplementary Table 5) although nominally
significantly enrichments were observed among several predefined candidate pathways
(Extended Data Table 1). A fuller exploratory analysis of the data will be presented
elsewhere.
Overlap with rare mutations
CNVs associated with schizophrenia overlap with those associated with ASD and
intellectual disability9 as do genes with deleterious de novo mutations. 34 Here, we find
significant overlap between genes in the schizophrenia GWAS associated intervals and those
with de novo nonsynonymous mutations in schizophrenia (P=0.0061) (Extended Data Table
2), suggesting that mechanistic studies of rare genetic variation in schizophrenia will be
informative for schizophrenia more widely. We also find evidence for overlap between
genes in schizophrenia GWAS regions and those with de novo nonsynonymous mutations in
et al. Page 5
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sintellectual disability (P=0.00024) and ASD (P=0.035), providing further support for the
hypothesis that these disorders have partly overlapping pathophysiologies.9,34
Polygenic Risk Score Profiling
Previous studies have shown that risk profile scores (RPS) constructed from alleles showing
modest association with schizophrenia in a discovery GWAS can predict case-control status
in independent samples, albeit with low sensitivity and specificity.10,11,16 This finding was
robustly confirmed in the present study. The estimate of Nagelkerke R2 (a measure of
variance in case-control status explained) depends on the specific target dataset and
threshold (PT) for selecting risk alleles for RPS analysis (Extended Data Figure 5 & 6a).
However, using the same target sample as earlier studies and PT =0.05, R2 is now increased
from 0.03 (reference10) to 0.184 (Extended Data Figure 5). Assuming a liability-threshold
model, a lifetime risk of 1%, independent SNP effects, and adjusting for case-control
ascertainment, RPS now explains about 7% of variation on the liability scale46 to
schizophrenia across the samples (Extended Data Figure 6b), about half of which (3.4%) is
explained by genome-wide significant loci.
We also evaluated the capacity of RPS to predict case-control status using a standard
epidemiological approach to a continuous risk factor. We illustrate this in three samples,
each with different ascertainment schemes (Figure 3). The Danish sample is population-
based (i.e. inpatient and outpatient facilities), the Sweden sample is based on all cases
hospitalized for schizophrenia in Sweden, and the MGS study was ascertained specially for
genetic studies from clinical sources in the US and Australia. We grouped individuals into
RPS deciles and estimated the odds ratios for affected status for each decile with reference
to the lowest risk decile. The odds ratios increased with greater number of schizophrenia risk
alleles in each sample, maximizing for the tenth decile in all samples: Denmark 7.8 (95% CI
4.4-13.9), Sweden 15.0 (95% CI 12.1-18.7), and MGS 20.3 (95% CI 14.7-28.2). Given the
need for measures that index liability to schizophrenia,47,48 the ability to stratify individuals
by RPS offers new opportunities for clinical and epidemiological research. Nevertheless, we
stress that the sensitivity and specificity of RPS do not support its use as a predictive test.
For example in the Danish epidemiological sample, the area under the receiver operating
curve is only 0.62 (Extended Data Figure 6c, Supplementary Table 6).
Finally, seeking evidence for non-additive effects on risk, we tested for statistical interaction
between all pairs of 125 autosomal SNPs that reached genome-wide significance. P-values
for the interaction terms were distributed according to the null, and no interaction was
significant after correction for multiple comparisons. Thus, we find no evidence for epistatic
or non-additive effects between the significant loci (Extended Data Figure 7). It is possible
that such effects could be present between other loci, or occur in the form of higher order
interactions.
Discussion
In the largest molecular genetic study of schizophrenia ever conducted, or indeed of any
neuropsychiatric disorder, we demonstrate the power of GWAS to identify large numbers of
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srisk loci. We also show that the use of alternative ascertainment and diagnostic schemes
designed to rapidly increase sample size does not inevitably introduce a crippling degree of
heterogeneity. That this is true for a phenotype like schizophrenia where there are no
biomarkers or supportive diagnostic tests provides grounds to be optimistic about applying
GWAS to other disorders where diagnosis is similarly clinician-based, and recruitment
traditionally constrained by the need for expensive and time consuming assessments.
We further show that the associations are not randomly distributed across genes of all
classes and function; rather they converge upon genes that are expressed in certain tissues
and cellular types. The findings include molecules that are the current, or the most
promising, targets for therapeutics, and point to systems that align with the predominant
aetiological hypotheses of the disorder. This suggests that the many novel findings we report
also provide a aetiologically relevant foundation for mechanistic and treatment development
studies. We additionally find overlap between genes affected by rare variants in
schizophrenia and those within GWAS loci, and broad convergence in the functions of some
of the clusters of genes implicated by both sets of genetic variants, particularly genes related
to abnormal glutamatergic synaptic and calcium channel function. How variation in these
genes impact function to increase risk for schizophrenia cannot be answered by genetics, but
the overlap strongly suggests that common and rare variant studies are complementary
rather than antagonistic, and that mechanistic studies driven by rare genetic variation will be
informative for schizophrenia.
Extended Data
Extended Data Figure 1. Homogeneity of Effects Across Studies
Plot of the first two principal components (PC) from principal components analysis (PCA)
of the logistic regression β coefficients for autosomal genome-wide significant associations.
The input data were the β coefficients from 52 samples for 112 independent SNP
associations (excluding 3 chrX SNPs and 13 SNPs with missing values in Asian samples).
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sPCAs were weighted by the number of cases. Each circle shows the location of a study on
PC1 and PC2. Circle size and colour are proportional to the number of cases in each sample
(larger and redder circles correspond to more cases). Most samples cluster. Outliers had
either small numbers of cases (“small”) or were genotyped on older arrays. Abbreviations.
a500 (Affymetrix 500K); a5 (Affymetrix 5.0). Studies that did not use conventional research
interviews are in the central cluster (CLOZUK, Sweden, and Denmark-Aarhus studies).
Extended Data Figure 2. Quantile-quantile plot
Quantile-quantile plot of GWAS meta-analysis. Expected −log10(P) -values are those
expected under the null hypothesis. For clarity, we avoided expansion of the Y-axis by
setting association P-values < 10−12 to 10−12. The shaded area surrounded by a red line
indicates the 95% confidence interval under the null. Lambda is the observed median χ2 test
statistic divided by the median expected χ2 test statistic under the null.
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sExtended Data Figure 3. LD Score regression consistent with polygenic inheritance
The relationship between marker χ2 association statistics and linkage disequilibrium (LD) as
measured by the LD Score. LD Score is the sum of the r2 values between a variant and all
other known variants within a 1 cM window, and quantifies the amount of genetic variation
tagged by that variant. Variants were grouped into 50 equal-sized bins based on LD Score
rank. LD Score Bin and Mean χ2 denotes mean LD score and test statistic for markers each
bin. We simulated (Supplementary Text) test statistics under two scenarios: (a) no true
association, inflation due to population stratification (b) polygenic inheritance (λGC =1.32),
in which we assigned independent and identically distributed per-normalized-genotype
effects to a randomly selected subset of variants. Panel (c) present results from the PGC
schizophrenia GWAS (λGC =1.48). The real data are strikingly similar to the simulated data
summarized in (b) but not (a). The intercept estimates the inflation in the mean χ2 that
results from confounding biases, such as cryptic relatedness or population stratification.
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sThus, the intercept of 1.066 for the schizophrenia GWAS suggests that ~90% of the inflation
in the mean χ2 results from polygenic signal. The results of the simulations are also
consistent with theoretical expectation (see Supplementary Text).
Extended Data Figure 4. Enrichment of Associations in Tissues and Cells
Genes whose transcriptional start is nearest to the most associated SNP at each
schizophrenia-associated locus were tested for enriched expression in a) purified brain cell
subsets obtained from mouse ribotagged lines41. The red dotted line indicates P=0.05.
Extended Data Figure 5. MGS Risk Profile Score Analysis
Polygenic risk profile score (RPS) analyses using the MGS18 sample as target, and deriving
risk alleles from three published schizophrenia datasets (X-axis): ISC (2615 cases and 3338
controls) 10, PGC1 (excluding MGS, 9320 cases and 10,228 controls) 16, and the current
meta analysis (excluding MGS) with 32,838 cases and 44,357 controls. Samples sizes differ
slightly from original publication due to different analytical procedures. This shows the
increasing RPS prediction with increasing training dataset size reflecting improved precision
et al. Page 10
Nature. Author manuscript; available in PMC 2015 January 24.
 
E
u
r
o
p
e
 
P
M
C
 
F
u
n
d
e
r
s
 
A
u
t
h
o
r
 
M
a
n
u
s
c
r
i
p
t
s
 
E
u
r
o
p
e
 
P
M
C
 
F
u
n
d
e
r
s
 
A
u
t
h
o
r
 
M
a
n
u
s
c
r
i
p
t
sof estimates of the SNP effect sizes. The proportion of variance explained (Y-axis;
Nagelkerke’s R2) was computed by comparison of a full model (covariates + RPS) score to
a reduced model (covariates only). Ten different P-value thresholds (PT) for selecting risk
alleles are denoted by the colour of each bar (legend above plot). For significance testing,
see the bottom legend which denotes the P-value for the test that R2 is different from zero.
All numerical data and methods used to generate these plots are available in Supplementary
Tables 6, 7, and Supplementary Text.
Extended Data Figure 6. Risk Profile Score Analysis
We defined 40 target subgroups of the primary GWAS dataset and performed 40 leave-one-
out GWAS analyses (see Supplementary Material) from which we derived risk alleles for
RPS analysis (X-axis) for each target subgroup. a) The proportion of variance explained (Y-
axis; Nagelkerke’s R2) was computed for each target by comparison of a full model
(covariates + RPS) score to a reduced model (covariates only). For clarity, 3 different P-
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svalue thresholds (PT) are presented denoted by the colour of each bar (legend above plot) as
for Extended Data Figure 5 but for clarity we restrict to fewer P-value thresholds (PT of
5×10−8, 1×10−4, and 0.05) and removed the significance values. (b) The proportion of
variance on the liability scale from risk scores calculated at the PT 0.05 with 95% CI bar
assuming baseline population disease risk of 1%. (C) Area under the receiver operating
curve (AUC). All numerical data and methods used to generate these plots are available in
Supplementary Tables 6, 7, and Supplementary Text.
Extended Data Figure 7. Epistasis
Quantile-quantile plot for all pair-wise (N=7750) combinations of the 125 independent
autosomal genome-wide significant SNPs tested for non-additive effects on risk using case-
control datasets of European ancestry (32,405 cases and 42,221 controls). We included as
covariates the principal components from the main analysis as well as a study indicator. The
interaction model is described by:
X1 and X2 are genotypes at the two loci, X1*X2 is the interaction between the two genotypes
modeled in a multiplicative fashion, X4 is the vector of principal components, X5 is the
vector of study indicator variables. Each β is the regression coefficient in the generalized
linear model using logistic regression. The overall distribution of P-values did not deviate
from the null and the smallest P-value (4.28×10−4) did not surpass the Bonferroni correction
threshold (p=0.05/7750= 6.45×10−6). The line x=y indicates the expected null distribution
with the grey area bounded by red lines indicating the expected 95% confidence interval for
the null.
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sExtended Data Table 1
ALIGATOR and INRICH
Gene sets that have been reported to be enriched for schizophrenia associations and or rare
mutations were tested for enrichment for genome wide significant associations using
ALIGATOR44 and INRICH45. Specifically, we tested the glutamatergic postsynaptic
proteins comprising activity-regulated cytoskeleton-associated protein (ARC) and N-methyl-
d-aspartate receptor (NMDAR) complexes33-35, other curated synaptic gene-sets14,51,
targets of fragile X mental retardation protein (FMRP) 33-35, calcium channels 11,33, and
TargetScan predicted MIR137 sets11,16. The MIR137 TargetScan sets contain
computationally predicted conserved miRNA target sites in 3′UTRs of human genes52. The
current version is v6, but the version used in the prior PGC SCZ report16 was based on v5
(filtered for a probability of conserved targeting > 0.9). We report the results of both
analyses for consistency with previous work. The association at the extended MHC complex
was not included given the extensive linkage disequilibrium at this region spans large
numbers of genes. NA means that the pathway in question contained fewer than 2 significant
genes (for ALIGATOR) or regions (INRICH).
SET ALIGATOR INRICH
Postsynaptic sets
  ARC NA 1
  NMDAR NA 0.458
Curated pre- and postsynaptic sets
  Cell adhesion and trans8 synaptic signalling 0.902 0.44
  Structural plasticity NA NA
  Excitability NA NA
FMRP sets
  FMRP 0.0066 5.00E-05
MIR137 sets
  Targetscan v5 with PCT > 0.9 0.0371 0.0103
  Targetscan v6.2 0.059 0.0024
Calcium signalling sets
  CACN* channel subunits 0.0338 0.022
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sExtended Data Table 2
de novo overlap
Test of overlap between genes mapping to schizophrenia-associated loci in the present study
and genes affected by nonsynonymous (NS) de novo mutations. Enrichment was calculated
using the dnenrich permutation framework as described34. Genes within the GWS loci were
weighted by 1/N, where N is the number of coding genes within each associated locus. The
observed test statistic (stat) is the sum of weights of genes impacted by de novo mutations.
The expected test statistics are calculated by averaging over 50,000 permuted de novo
mutation sets. Genes within schizophrenia-associated loci affected by de novo mutations are
listed (multiple hits listed in parentheses). Cohorts: SCZ = schizophrenia, ID = intellectual
disability, ASD = autism spectrum disorder. All mutations analysed annotated according to a
unified system (see supplementary tables 1 and 2 of ref34). Genes with LoF de novo
mutations are underlined and in italics.
Disease group NS (N) P
0 NS in
PGC2
loci
Observed (stat) Expected (stat) Genes
SCZ 702 0.0061 25 10.97 5.27
CACNACI(x2) CCDC39
CDCH(x2) CRCL CUL3
DPEP2 DPYD(x2) EP300
ESAM GRIN2A LRP1
NCAN PDCDCC PTPRF
RIMSC SBNOC SGSM2
SLC7A6 STAGC
TMEM2C9 ZDHHC5
ZNF536
ID 141 0.00002 11 6.87 1.05
GRIAC GRIN2A(x2)
LRPC NEKC NGEF
SATB2 SREBF2 STAGC
TCFH(x2)
ASD 789 0.035 19 9.99 5.93
APH1A CNOTC CSMDC
CUL3 CYPC7AC
CYP26BC EPHX2 LRPC
MAPK3 MEF2C MPP6
MYOC5A NISCH
PBRMC PRKDC RIMS1
TSNAREC WDR55
ZNF80HA
Controls 434 0.15 16 4.88 3.28
ANKRDHH CCCorf87
CCDC39 CDK2APC
CHRMH DPEP2 EP300
LRPC LRRCH8
MAN2AC MYOCA
OSBPL3 RAIC SF3BC
SREBF2 TLE3
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
Authors
Schizophrenia Working Group of the Psychiatric Genomics Consortium, Stephan
Ripke1,2, Benjamin M Neale1,2,3,4, Aiden Corvin5, James TR Walters6, Kai-How
Farh1, Peter A Holmans6,7, Phil Lee1,2,4, Brendan Bulik-Sullivan1,2, David A
et al. Page 14
Nature. Author manuscript; available in PMC 2015 January 24.
 
E
u
r
o
p
e
 
P
M
C
 
F
u
n
d
e
r
s
 
A
u
t
h
o
r
 
M
a
n
u
s
c
r
i
p
t
s
 
E
u
r
o
p
e
 
P
M
C
 
F
u
n
d
e
r
s
 
A
u
t
h
o
r
 
M
a
n
u
s
c
r
i
p
t
sCollier8,9, Hailiang Huang1,3, Tune H Pers3,10,11, Ingrid Agartz12,13,14, Esben
Agerbo15,16,17, Margot Albus18, Madeline Alexander19, Farooq Amin20,21, Silviu A
Bacanu22, Martin Begemann23, Richard A Belliveau Jr2, Judit Bene24,25, Sarah E
Bergen2,26, Elizabeth Bevilacqua2, Tim B Bigdeli22, Donald W Black27, Richard
Bruggeman28, Nancy G Buccola29, Randy L Buckner30,31,32, William Byerley33,
Wiepke Cahn34, Guiqing Cai35,36, Dominique Campion37, Rita M Cantor38,
Vaughan J Carr39,40, Noa Carrera6, Stanley V Catts39,41, Kimberley D Chambert2,
Raymond CK Chan42, Ronald YL Chan43, Eric YH Chen44, Wei Cheng45, Eric FC
Cheung46, Siow Ann Chong47, C Robert Cloninger48, David Cohen49, Nadine
Cohen50, Paul Cormican5, Nick Craddock6,7, James J Crowley51, David Curtis52,53,
Michael Davidson54, Kenneth L Davis36, Franziska Degenhardt55,56, Jurgen Del
Favero57, Ditte Demontis17,58,59, Dimitris Dikeos60, Timothy Dinan61, Srdjan
Djurovic14,62, Gary Donohoe5,63, Elodie Drapeau36, Jubao Duan64,65, Frank
Dudbridge66, Naser Durmishi67, Peter Eichhammer68, Johan Eriksson69,70,71,
Valentina Escott-Price6, Laurent Essioux72, Ayman H Fanous73,74,75,76, Martilias S
Farrell51, Josef Frank77, Lude Franke78, Robert Freedman79, Nelson B Freimer80,
Marion Friedl81, Joseph I Friedman36, Menachem Fromer1,2,4,82, Giulio Genovese2,
Lyudmila Georgieva6, Ina Giegling81,83, Paola Giusti-Rodríguez51, Stephanie
Godard84, Jacqueline I Goldstein1,3, Vera Golimbet85, Srihari Gopal86, Jacob
Gratten87, Lieuwe de Haan88, Christian Hammer23, Marian L Hamshere6, Mark
Hansen89, Thomas Hansen17,90, Vahram Haroutunian36,91,92, Annette M
Hartmann81, Frans A Henskens39,93,94, Stefan Herms55,56,95, Joel N
Hirschhorn3,11,96, Per Hoffmann55,56,95, Andrea Hofman55,56, Mads V Hollegaard97,
David M Hougaard97, Masashi Ikeda98, Inge Joa99, Antonio Julià100, René S
Kahn101, Luba Kalaydjieva102,103, Sena Karachanak-Yankova104, Juha
Karjalainen78, David Kavanagh6, Matthew C Keller105, James L Kennedy106,107,108,
Andrey Khrunin109, Yunjung Kim51, Janis Klovins110, James A Knowles111, Bettina
Konte81, Vaidutis Kucinskas112, Zita Ausrele Kucinskiene112, Hana Kuzelova-
Ptackova113,114, Anna K Kähler26, Claudine Laurent19,115, Jimmy Lee47,116, S
Hong Lee87, Sophie E Legge6, Bernard Lerer117, Miaoxin Li118, Tao Li119, Kung-
Yee Liang120, Jeffrey Lieberman121, Svetlana Limborska109, Carmel M
Loughland39,122, Jan Lubinski123, Jouko Lönnqvist124, Milan Macek113,114, Patrik
KE Magnusson26, Brion S Maher125, Wolfgang Maier126, Jacques Mallet127, Sara
Marsal100, Manuel Mattheisen17,58,59,128, Morten Mattingsdal14,129, Robert W
McCarley130,131, Colm McDonald132, Andrew M McIntosh133,134, Sandra Meier77,
Carin J Meijer88, Bela Melegh24,25, Ingrid Melle14,135, Raquelle I Mesholam-
Gately130,136, Andres Metspalu137, Patricia T Michie39,138, Lili Milani137, Vihra
Milanova139, Younes Mokrab8, Derek W Morris5,63, Ole Mors17,58,140, Kieran C
Murphy141, Robin M Murray142, Inez Myin-Germeys143, Bertram Müller-
Myhsok144,145,146, Mari Nelis137, Igor Nenadic147, Deborah A Nertney148, Gerald
Nestadt149, Kristin K Nicodemus150, Liene Nikitina-Zake110, Laura Nisenbaum151,
Annelie Nordin152, Eadbhard O’Callaghan153, Colm O’Dushlaine2, F Anthony
O’Neill154, Sang-Yun Oh155, Ann Olincy79, Line Olsen17,90, Jim Van Os143,156,
Psychosis Endophenotypes International Consortium157, Christos Pantelis39,158,
George N Papadimitriou60, Sergi Papiol23, Elena Parkhomenko36, Michele T
et al. Page 15
Nature. Author manuscript; available in PMC 2015 January 24.
 
E
u
r
o
p
e
 
P
M
C
 
F
u
n
d
e
r
s
 
A
u
t
h
o
r
 
M
a
n
u
s
c
r
i
p
t
s
 
E
u
r
o
p
e
 
P
M
C
 
F
u
n
d
e
r
s
 
A
u
t
h
o
r
 
M
a
n
u
s
c
r
i
p
t
sPato111, Tiina Paunio159,160, Milica Pejovic-Milovancevic161, Diana O Perkins162,
Olli Pietiläinen160,163, Jonathan Pimm53, Andrew J Pocklington6, John Powell142,
Alkes Price164, Ann E Pulver149, Shaun M Purcell82, Digby Quested165, Henrik B
Rasmussen17,90, Abraham Reichenberg36, Mark A Reimers166, Alexander L
Richards6,7, Joshua L Roffman30,32, Panos Roussos82,167, Douglas M Ruderfer82,
Veikko Salomaa71, Alan R Sanders64,65, Ulrich Schall39,122, Christian R
Schubert168, Thomas G Schulze77,169, Sibylle G Schwab170, Edward M Scolnick2,
Rodney J Scott39,171,172, Larry J Seidman130,136, Jianxin Shi173, Engilbert
Sigurdsson174, Teimuraz Silagadze175, Jeremy M Silverman36,176, Kang Sim47,
Petr Slominsky109, Jordan W Smoller2,4, Hon-Cheong So43, Chris C A Spencer177,
Eli A Stahl3,82, Hreinn Stefansson178, Stacy Steinberg178, Elisabeth Stogmann179,
Richard E Straub180, Eric Strengman181,182, Jana Strohmaier77, T Scott Stroup121,
Mythily Subramaniam47, Jaana Suvisaari124, Dragan M Svrakic48, Jin P
Szatkiewicz51, Erik Söderman12, Srinivas Thirumalai183, Draga Toncheva104, Sarah
Tosato184, Juha Veijola185,186, John Waddington187, Dermot Walsh188, Dai
Wang86, Qiang Wang119, Bradley T Webb22, Mark Weiser54, Dieter B
Wildenauer189, Nigel M Williams190, Stephanie Williams51, Stephanie H Witt77,
Aaron R Wolen166, Emily HM Wong43, Brandon K Wormley22, Hualin Simon Xi191,
Clement C Zai106,107, Xuebin Zheng192, Fritz Zimprich179, Naomi R Wray87, Kari
Stefansson178, Peter M Visscher87, Wellcome Trust Case-Control Consortium 2193,
Rolf Adolfsson152, Ole A Andreassen14,135, Douglas HR Blackwood134, Elvira
Bramon194, Joseph D Buxbaum35,36,91,195, Anders D Børglum17,58,59,140, Sven
Cichon55,56,95,196, Ariel Darvasi197, Enrico Domenici198, Hannelore Ehrenreich23,
Tõnu Esko3,11,96,137, Pablo V Gejman64,65, Michael Gill5, Hugh Gurling53, Christina
M Hultman26, Nakao Iwata98, Assen V Jablensky39,199,200,201, Erik G Jönsson12,
Kenneth S Kendler202, George Kirov6, Jo Knight106,107,108, Todd Lencz203,204,205,
Douglas F Levinson19, Qingqin S Li86, Jianjun Liu192,206, Anil K Malhotra203,204,205,
Steven A McCarroll2,96, Andrew McQuillin53, Jennifer L Moran2, Preben B
Mortensen15,16,17, Bryan J Mowry87,207, Markus M Nöthen55,56, Roel A
Ophoff38,80,208, Michael J Owen6,7, Aarno Palotie4,163,209, Carlos N Pato111, Tracey
L Petryshen130,209,210, Danielle Posthuma211,212,213, Marcella Rietschel77, Brien P
Riley202, Dan Rujescu81,83, Pak C Sham214, Pamela Sklar82,91,167, David St
Clair215, Daniel R Weinberger180,216, Jens R Wendland168, Thomas Werge17,90,217,
Mark J Daly1, Patrick F Sullivan26,51,162, and Michael C O’Donovan6,7
Affiliations
1Analytic and Translational Genetics Unit, Massachusetts General Hospital, Boston,
MA, USA.
2Stanley Center for Psychiatric Research, Broad Institute of MIT and Harvard,
Cambridge, MA, USA.
3Medical and Population Genetics Program, Broad Institute of MIT and Harvard,
Cambridge, MA, USA.
4Psychiatric and Neurodevelopmental Genetics Unit, Massachusetts General
Hospital, Boston, MA, USA.
et al. Page 16
Nature. Author manuscript; available in PMC 2015 January 24.
 
E
u
r
o
p
e
 
P
M
C
 
F
u
n
d
e
r
s
 
A
u
t
h
o
r
 
M
a
n
u
s
c
r
i
p
t
s
 
E
u
r
o
p
e
 
P
M
C
 
F
u
n
d
e
r
s
 
A
u
t
h
o
r
 
M
a
n
u
s
c
r
i
p
t
s5Neuropsychiatric Genetics Research Group, Department of Psychiatry, Trinity
College Dublin, Ireland.
6MRC Centre for Neuropsychiatric Genetics and Genomics, Institute of
Psychological Medicine and Clinical Neurosciences, School of Medicine, Cardiff
University, Cardiff, UK.
7National Centre for Mental Health, Cardiff University, Cardiff, Wales.
8Eli Lilly and Company Limited, Erl Wood Manor, Sunninghill Road, Windlesham,
Surrey, UK.
9Social, Genetic and Developmental Psychiatry Centre, Institute of Psychiatry,
King’s College London, London, UK.
10Center for Biological Sequence Analysis, Department of Systems Biology,
Technical University of Denmark, Lyngby, Denmark.
11Division of Endocrinology and Center for Basic and Translational Obesity
Research, Boston Children’s Hospital, Boston, MA, USA.
12Department of Clinical Neuroscience, Karolinska Institutet, Stockholm, Sweden.
13Department of Psychiatry, Diakonhjemmet Hospital, Oslo, Norway.
14NORMENT, KG Jebsen Centre for Psychosis Research, Institute of Clinical
Medicine, University of Oslo, Oslo, Norway.
15Centre for Integrative Register-based Research, CIRRAU, Aarhus University,
Aarhus, Denmark.
16National Centre for Register-based Research, Aarhus University, Aarhus,
Denmark.
17The Lundbeck Foundation Initiative for Integrative Psychiatric Research, iPSYCH,
Denmark.
18State Mental Hospital, Haar, Germany.
19Department of Psychiatry and Behavioral Sciences, Stanford University, Stanford,
CA, USA.
20Department of Psychiatry and Behavioral Sciences, Atlanta Veterans Affairs
Medical Center, Atlanta, GA, USA.
21Department of Psychiatry and Behavioral Sciences, Emory University, Atlanta,
GA, USA.
22Virginia Institute for Psychiatric and Behavioral Genetics, Department of
Psychiatry, Virginia Commonwealth University, Richmond, VA, USA.
23Clinical Neuroscience, Max Planck Institute of Experimental Medicine, Göttingen,
Germany.
24Department of Medical Genetics, University of Pécs, Pécs, Hungary.
et al. Page 17
Nature. Author manuscript; available in PMC 2015 January 24.
 
E
u
r
o
p
e
 
P
M
C
 
F
u
n
d
e
r
s
 
A
u
t
h
o
r
 
M
a
n
u
s
c
r
i
p
t
s
 
E
u
r
o
p
e
 
P
M
C
 
F
u
n
d
e
r
s
 
A
u
t
h
o
r
 
M
a
n
u
s
c
r
i
p
t
s25Szentagothai Research Center, University of Pécs, Pécs, Hungary.
26Department of Medical Epidemiology and Biostatistics, Karolinska Institutet,
Stockholm, Sweden.
27Department of Psychiatry, University of Iowa Carver College of Medicine, Iowa
City, IA, USA.
28University Medical Center Groningen, Department of Psychiatry, University of
Groningen, The Netherlands.
29School of Nursing, Louisiana State University Health Sciences Center, New
Orleans, LA, USA.
30Athinoula A. Martinos Center, Massachusetts General Hospital, Boston, MA, USA.
31Center for Brain Science, Harvard University, Cambridge MA, USA.
32Department of Psychiatry, Massachusetts General Hospital, Boston, MA, USA.
33Department of Psychiatry, University of California at San Francisco, San
Francisco, CA, USA.
34University Medical Center Utrecht, Department of Psychiatry, Rudolf Magnus
Institute of Neuroscience, The Netherlands.
35Department of Human Genetics, Icahn School of Medicine at Mount Sinai, New
York, NY, USA.
36Department of Psychiatry, Icahn School of Medicine at Mount Sinai, New York,
NY, USA.
37Centre Hospitalier du Rouvray and INSERM U1079 Faculty of Medicine, Rouen,
France.
38Department of Human Genetics, David Geffen School of Medicine, University of
California, Los Angeles, CA, USA.
39Schizophrenia Research Institute, Sydney, Australia.
40School of Psychiatry, University of New South Wales, Sydney, Australia.
41Royal Brisbane and Women’s Hospital, University of Queensland, Brisbane,
Australia.
42Institute of Psychology, Chinese Academy of Science, Beijing, PR China.
43Department of Psychiatry, Li Ka Shing Faculty of Medicine, The University of
Hong Kong, Hong Kong SAR, PR China.
44Department of Psychiatry and State Ket Laboratory for Brain and Cognitive
Sciences, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong
Kong SAR, PR China.
45Department of Computer Science, University of North Carolina, Chapel Hill, NC,
USA.
et al. Page 18
Nature. Author manuscript; available in PMC 2015 January 24.
 
E
u
r
o
p
e
 
P
M
C
 
F
u
n
d
e
r
s
 
A
u
t
h
o
r
 
M
a
n
u
s
c
r
i
p
t
s
 
E
u
r
o
p
e
 
P
M
C
 
F
u
n
d
e
r
s
 
A
u
t
h
o
r
 
M
a
n
u
s
c
r
i
p
t
s46Castle Peak Hospital, Hong Kong SAR, PR China.
47Institute of Mental Health, Singapore.
48Department of Psychiatry, Washington University, St. Louis, MO, USA.
49Department of Child and Adolescent Psychiatry, Pierre and Marie Curie Faculty of
Medicine and Brain and Spinal Cord Institute (ICM), Paris, France.
50Formerly of Neuroscience Therapeutic Area, Janssen Research and
Development, LLC, Raritan, NJ, USA.
51Department of Genetics, University of North Carolina, Chapel Hill, NC, USA.
52Department of Psychological Medicine, Queen Mary University of London, UK.
53Molecular Psychiatry Laboratory, Division of Psychiatry, University College
London, UK.
54Sheba Medical Center, Tel Hashomer, Israel.
55Department of Genomics, Life and Brain Center, Bonn, Germany.
56Institute of Human Genetics, University of Bonn, Bonn, Germany.
57Applied Molecular Genomics Unit, VIB Department of Molecular Genetics,
University of Antwerp, Antwerp, Belgium.
58Centre for Integrative Sequencing, iSEQ, Aarhus University, Aarhus, Denmark.
59Department of Biomedicine, Aarhus University, Aarhus, Denmark.
60First Department of Psychiatry, University of Athens Medical School, Athens,
Greece.
61Department of Psychiatry, University College Cork, Ireland.
62Department of Medical Genetics, Oslo University Hospital, Oslo, Norway.
63Cognitive Genetics and Therapy Group, School of Psychology and Discipline of
Biochemistry, National University of Ireland Galway, Ireland.
64Department of Psychiatry and Behavioral Neuroscience, University of Chicago,
Chicago, IL, USA.
65Department of Psychiatry and Behavioral Sciences, NorthShore University
HealthSystem, Evanston, IL, USA.
66Department of Non-Communicable Disease Epidemiology, London School of
Hygiene and Tropical Medicine, London, UK.
67Department of Child and Adolescent Psychiatry, University Clinic of Psychiatry,
Skopje, Republic of Macedonia.
68Department of Psychiatry, University of Regensburg, Regensburg, Germany.
69Department of General Practice, Helsinki University Central Hospital, Helsinki,
Finland.
et al. Page 19
Nature. Author manuscript; available in PMC 2015 January 24.
 
E
u
r
o
p
e
 
P
M
C
 
F
u
n
d
e
r
s
 
A
u
t
h
o
r
 
M
a
n
u
s
c
r
i
p
t
s
 
E
u
r
o
p
e
 
P
M
C
 
F
u
n
d
e
r
s
 
A
u
t
h
o
r
 
M
a
n
u
s
c
r
i
p
t
s70Folkhälsan Research Center, Helsinki, Finland.
71National Institute for Health and Welfare, Helsinki, Finland.
72Translational Technologies and Bioinformatics, Pharma Research and Early
Development, F.Hoffman-La Roche, Basel, Switzerland.
73Department of Psychiatry, Georgetown University School of Medicine,
Washington DC, USA.
74Department of Psychiatry, Keck School of Medicine of the University of Southern
California, Los Angeles, CA, USA.
75Department of Psychiatry, Virginia Commonwealth University School of Medicine,
Richmond, VA, USA.
76Mental Health Service Line, Washington VA Medical Center, Washington DC,
USA.
77Department of Genetic Epidemiology in Psychiatry, Central Institute of Mental
Health, Medical Faculty Mannheim, University of Heidelberg, Heidelberg, Germany.
78Department of Genetics, University of Groningen, University Medical Centre
Groningen, The Netherlands.
79Department of Psychiatry, University of Colorado Denver, Aurora, CO, USA.
80Center for Neurobehavioral Genetics, Semel Institute for Neuroscience and
Human Behavior, University of California, Los Angeles, CA, USA.
81Department of Psychiatry, University of Halle, Halle, Germany.
82Division of Psychiatric Genomics, Department of Psychiatry, Icahn School of
Medicine at Mount Sinai, New York, NY, USA.
83Department of Psychiatry, University of Munich, Munich, Germany.
84Departments of Psychiatry and Human and Molecular Genetics, INSERM, Institut
de Myologie, Hôpital de la Pitiè-Salpêtrière, Paris, France.
85Mental Health Research Centre, Russian Academy of Medical Sciences, Moscow,
Russia.
86Neuroscience Therapeutic Area, Janssen Research and Development, LLC,
Raritan, NJ, USA.
87Queensland Brain Institute, The University of Queensland, Brisbane, Queensland,
Australia.
88Academic Medical Centre University of Amsterdam, Department of Psychiatry,
Amsterdam, The Netherlands.
89Illumina, Inc., La Jolla, CA, USA.
90Institute of Biological Psychiatry, MHC Sct. Hans, Mental Health Services
Copenhagen, Denmark.
et al. Page 20
Nature. Author manuscript; available in PMC 2015 January 24.
 
E
u
r
o
p
e
 
P
M
C
 
F
u
n
d
e
r
s
 
A
u
t
h
o
r
 
M
a
n
u
s
c
r
i
p
t
s
 
E
u
r
o
p
e
 
P
M
C
 
F
u
n
d
e
r
s
 
A
u
t
h
o
r
 
M
a
n
u
s
c
r
i
p
t
s91Friedman Brain Institute, Icahn School of Medicine at Mount Sinai, New York, NY,
USA.
92JJ Peters VA Medical Center, Bronx, NY, USA.
93Priority Research Centre for Health Behaviour, University of Newcastle,
Newcastle, Australia.
94School of Electrical Engineering and Computer Science, University of Newcastle,
Newcastle, Australia.
95Division of Medical Genetics, Department of Biomedicine, University of Basel,
Basel, Switzerland.
96Department of Genetics, Harvard Medical School, Boston, MA, USA.
97Section of Neonatal Screening and Hormones, Department of Clinical
Biochemistry, Immunology and Genetics, Statens Serum Institut, Copenhagen,
Denmark.
98Department of Psychiatry, Fujita Health University School of Medicine, Toyoake,
Aichi, Japan.
99Regional Centre for Clinical Research in Psychosis, Department of Psychiatry,
Stavanger University Hospital, Stavanger, Norway.
100Rheumatology Research Group, Vall d’Hebron Research Institute, Barcelona,
Spain.
101Department of Psychiatry, Rudolf Magnus Institute of Neuroscience, University
Medical Center Utrecht, Utrecht, The Netherlands.
102Centre for Medical Research, The University of Western Australia, Perth,
Western Australia, Australia.
103Perkins Institute for Medical Research, The University of Western Australia,
Perth, Western Australia, Australia.
104Department of Medical Genetics, Medical University, Sofia, Bulgaria.
105Department of Psychology, University of Colorado Boulder, Boulder, CO, USA.
106Campbell Family Mental Health Research Institute, Centre for Addiction and
Mental Health, Toronto, Ontario, Canada.
107Department of Psychiatry, University of Toronto, Toronto, Ontario, Canada.
108Institute of Medical Science, University of Toronto, Toronto, Ontario, Canada.
109Institute of Molecular Genetics, Russian Academy of Sciences, Moscow, Russia.
110Latvian Biomedical Research and Study Centre, Riga, Latvia.
111Department of Psychiatry and Zilkha Neurogenetics Institute, Keck School of
Medicine at University of Southern California, Los Angeles, CA, USA.
112Faculty of Medicine, Vilnius University, Vilnius, Lithuania.
et al. Page 21
Nature. Author manuscript; available in PMC 2015 January 24.
 
E
u
r
o
p
e
 
P
M
C
 
F
u
n
d
e
r
s
 
A
u
t
h
o
r
 
M
a
n
u
s
c
r
i
p
t
s
 
E
u
r
o
p
e
 
P
M
C
 
F
u
n
d
e
r
s
 
A
u
t
h
o
r
 
M
a
n
u
s
c
r
i
p
t
s1132nd Faculty of Medicine and University Hospital Motol, Prague, Czech Republic.
114Department of Biology and Medical Genetics, Charles University Prague, Prague,
Czech Republic.
115Pierre and Marie Curie Faculty of Medicine, Paris, France.
116Duke-NUS Graduate Medical School, Singapore.
117Department of Psychiatry, Hadassah-Hebrew University Medical Center,
Jerusalem, Israel.
118Centre for Genomic Sciences and Department of Psychiatry, Li Ka Shing Faculty
of Medicine, The University of Hong Kong, Hong Kong SAR, PR China.
119Mental Health Centre and Psychiatric Laboratory, West China Hospital, Sichuan
University, Chendu, Sichuan, PR China.
120Department of Biostatistics, Johns Hopkins University Bloomberg School of
Public Health, Baltimore, Maryland, USA.
121Department of Psychiatry, Columbia University, New York, NY, USA.
122Priority Centre for Translational Neuroscience and Mental Health, University of
Newcastle, Newcastle, Australia.
123Department of Genetics and Pathology, International Hereditary Cancer Center,
Pomeranian Medical University in Szczecin, Szczecin, Poland.
124Department of Mental Health and Substance Abuse Services; National Institute
for Health and Welfare, Helsinki, Finland.
125Department of Mental Health, Bloomberg School of Public Health, Johns Hopkins
University, Baltimore, MD, USA.
126Department of Psychiatry, University of Bonn, Bonn, Germany.
127Centre National de la Recherche Scientifique, Laboratoire de Génétique
Moléculaire de la Neurotransmission et des Processus Neurodégénératifs, Hôpital
de la Pitié Salpêtrière, Paris, France.
128Department of Genomics Mathematics, University of Bonn, Bonn, Germany.
129Research Unit, Sørlandet Hospital, Kristiansand, Norway.
130Department of Psychiatry, Harvard Medical School, Boston, MA, USA.
131VA Boston Health Care System, Brockton, MA, USA.
132Department of Psychiatry, National University of Ireland Galway, Ireland.
133Centre for Cognitive Ageing and Cognitive Epidemiology, University of
Edinburgh, UK.
134Division of Psychiatry, University of Edinburgh, Edinburgh, UK.
135Division of Mental Health and Addiction, Oslo University Hospital, Oslo, Norway.
et al. Page 22
Nature. Author manuscript; available in PMC 2015 January 24.
 
E
u
r
o
p
e
 
P
M
C
 
F
u
n
d
e
r
s
 
A
u
t
h
o
r
 
M
a
n
u
s
c
r
i
p
t
s
 
E
u
r
o
p
e
 
P
M
C
 
F
u
n
d
e
r
s
 
A
u
t
h
o
r
 
M
a
n
u
s
c
r
i
p
t
s136Massachusetts Mental Health Center Public Psychiatry Division of the Beth Israel
Deaconess Medical Center, Boston, MA, USA.
137Estonian Genome Center, University of Tartu, Tartu, Estonia.
138School of Psychology, University of Newcastle, Newcastle, Australia.
139First Psychiatric Clinic, Medical University, Sofia, Bulgaria.
140Department P, Aarhus University Hospital, Risskov, Denmark.
141Department of Psychiatry, Royal College of Surgeons in Ireland, Ireland.
142King’s College London, UK.
143Maastricht University Medical Centre, South Limburg Mental Health Research
and Teaching Network, EURON, Maastricht, The Netherlands.
144Institute of Translational Medicine, University Liverpool, UK.
145Max Planck Institute of Psychiatry, Munich, Germany.
146Munich Cluster for Systems Neurology (SyNergy), Munich, Germany.
147Department of Psychiatry and Psychotherapy, Jena University Hospital, Jena,
Germany.
148Department of Psychiatry, Queensland Brain Institute and Queensland Centre for
Mental Health Research, University of Queensland, Brisbane, Queensland,
Australia.
149Department of Psychiatry and Behavioral Sciences, Johns Hopkins University
School of Medicine, Baltimore, Maryland, USA.
150Department of Psychiatry, Trinity College Dublin, Ireland.
151Eli Lilly and Company, Lilly Corporate Center, Indianapolis, IN, USA.
152Department of Clinical Sciences, Psychiatry, Umeå University, Umeå, Sweden.
153DETECT Early Intervention Service for Psychosis, Blackrock, Dublin, Ireland.
154Centre for Public Health, Institute of Clinical Sciences, Queens University Belfast,
Belfast, UK.
155Lawrence Berkeley National Laboratory, University of California at Berkeley,
Berkeley, CA, USA.
156Institute of Psychiatry at King’s College London, London, UK.
157PEIC.
158Melbourne Neuropsychiatry Centre, University of Melbourne & Melbourne Health,
Melbourne, Australia.
159Department of Psychiatry, University of Helsinki, Finland.
160Public Health Genomics Unit, National Institute for Health and Welfare, Helsinki,
Finland.
et al. Page 23
Nature. Author manuscript; available in PMC 2015 January 24.
 
E
u
r
o
p
e
 
P
M
C
 
F
u
n
d
e
r
s
 
A
u
t
h
o
r
 
M
a
n
u
s
c
r
i
p
t
s
 
E
u
r
o
p
e
 
P
M
C
 
F
u
n
d
e
r
s
 
A
u
t
h
o
r
 
M
a
n
u
s
c
r
i
p
t
s161Medical Faculty, University of Belgrade, Belgrade, Serbia.
162Department of Psychiatry, University of North Carolina, Chapel Hill, NC, USA.
163Institute for Molecular Medicine Finland, FIMM, Helsinki, Finland.
164Department of Epidemiology, Harvard University, Boston, MA, USA.
165Department of Psychiatry, University of Oxford, Oxford, UK.
166Virginia Institute for Psychiatric and Behavioral Genetics, Virginia Commonwealth
University, Richmond, VA, USA.
167Institute for Multiscale Biology, Icahn School of Medicine at Mount Sinai, New
York, NY, USA.
168PharmaTherapeutics Clinical Research, Pfizer Worldwide Research and
Development, Cambridge, MA, USA.
169Department of Psychiatry and Psychotherapy, University of Gottingen, Göttingen,
Germany.
170Psychiatry and Psychotherapy Clinic, University of Erlangen, Germany.
171Hunter New England Health Service, Newcastle, Australia.
172School of Biomedical Sciences, University of Newcastle, Newcastle, Australia.
173Division of Cancer Epidemiology and Genetics, National Cancer Institute,
Bethesda, MD, USA.
174University of Iceland, Landspitali, National University Hospital, Reykjavik, Iceland.
175Department of Psychiatry and Drug Addiction, Tbilisi State Medical University
(TSMU), Tbilisi, Georgia.
176Research and Development, Bronx Veterans Affairs Medical Center, New York,
NY, USA.
177Wellcome Trust Centre for Human Genetics, Oxford, UK.
178deCODE Genetics, Reykjavik, Iceland.
179Department of Clinical Neurology, Medical University of Vienna, Austria.
180Lieber Institute for Brain Development, Baltimore, MD, USA.
181Department of Medical Genetics, University Medical Centre, Utrecht, The
Netherlands.
182Rudolf Magnus Institute of Neuroscience, University Medical Centre Utrecht, The
Netherlands.
183Berkshire Healthcare NHS Foundation Trust, Bracknell, UK.
184Section of Psychiatry, University of Verona, Verona, Italy.
185Department of Psychiatry, University of Oulu, Finland.
et al. Page 24
Nature. Author manuscript; available in PMC 2015 January 24.
 
E
u
r
o
p
e
 
P
M
C
 
F
u
n
d
e
r
s
 
A
u
t
h
o
r
 
M
a
n
u
s
c
r
i
p
t
s
 
E
u
r
o
p
e
 
P
M
C
 
F
u
n
d
e
r
s
 
A
u
t
h
o
r
 
M
a
n
u
s
c
r
i
p
t
s186University Hospital of Oulu, Oulu, Finland.
187Molecular and Cellular Therapeutics, Royal College of Surgeons in Ireland,
Dublin, Ireland.
188Health Research Board, Dublin, Ireland.
189Department of Psychiatry and Clinical Neurosciences, School of Psychiatry and
Clinical Neurosciences, Queen Elizabeth II Medical Centre, Perth, Western
Australia, Australia.
190Department of Psychological Medicine and Neurology, MRC Centre for
Neuropsychiatric Genetics and Genomics, School of Medicine, Cardiff University,
Cardiff, Wales, UK.
191Computational Sciences CoE, Pfizer Worldwide Research and Development,
Cambridge, MA, USA.
192Human Genetics, Genome Institute of Singapore, A*STAR, Singapore.
193WTCCC2.
194University College London, UK.
195Department of Neuroscience, Icahn School of Medicine at Mount Sinai, New
York, NY, USA.
196Institute of Neuroscience and Medicine (INM-1), Research Center Juelich,
Juelich, Germany.
197Department of Genetics, The Hebrew University of Jerusalem, Jerusalem, Israel.
198Neuroscience Discovery and Translational Area, Pharma Research and Early
Development, F.Hoffman-La Roche, Basel, Switzerland.
199School of Psychiatry and Clinical Neurosciences, The University of Western
Australia, Perth, Australia.
200The Perkins Institute of Medical Research, Perth, Australia.
201UWA Centre for Clinical Research in Neuropsychiatry.
202Virginia Institute for Psychiatric and Behavioral Genetics, Departments of
Psychiatry and Human and Molecular Genetics, Virginia Commonwealth University,
Richmond, VA, USA.
203The Feinstein Institute for Medical Research, Manhasset, NY, USA.
204The Hofstra NS-LIJ School of Medicine, Hempstead, NY, USA.
205The Zucker Hillside Hospital, Glen Oaks, NY, USA.
206Saw Swee Hock School of Public Health, National University of Singapore,
Singapore.
207Queensland Centre for Mental Health Research, University of Queensland,
Brisbane, Queensland, Australia.
et al. Page 25
Nature. Author manuscript; available in PMC 2015 January 24.
 
E
u
r
o
p
e
 
P
M
C
 
F
u
n
d
e
r
s
 
A
u
t
h
o
r
 
M
a
n
u
s
c
r
i
p
t
s
 
E
u
r
o
p
e
 
P
M
C
 
F
u
n
d
e
r
s
 
A
u
t
h
o
r
 
M
a
n
u
s
c
r
i
p
t
s208Department of Psychiatry, Brain Center Rudolf Magnus, University Medical
Center Utrecht, The Netherlands.
209The Broad Institute of MIT and Harvard, Cambridge, MA, USA.
210Center for Human Genetic Research and Department of Psychiatry,
Massachusetts General Hospital, Boston, MA, USA.
211Department of Child and Adolescent Psychiatry, Erasmus University Medical
Centre, Rotterdam, The Netherlands.
212Department of Complex Trait Genetics, Neuroscience Campus Amsterdam, VU
University Medical Center Amsterdam, Amsterdam, The Netherlands.
213Department of Functional Genomics, Center for Neurogenomics and Cognitive
Research, Neuroscience Campus Amsterdam, VU University, Amsterdam, The
Netherlands.
214Centre for Genomic Sciences, State Ket Laboratory for Brain and Cognitive
Sciences, and Department of Psychiatry, Li Ka Shing Faculty of Medicine, The
University of Hong Kong, Hong Kong SAR, PR China.
215University of Aberdeen, Institute of Medical Sciences, Aberdeen, Scotland, UK.
216Departments of Psychiatry, Neurology, Neuroscience and Institute of Genetic
Medicine, Johns Hopkins School of Medicine, Baltimore, MD, USA.
217Department of Clinical Medicine, University of Copenhagen, Copenhagen,
Denmark.
Acknowledgments
Core funding for the Psychiatric Genomics Consortium is from the US National Institute of Mental Health (U01
MH094421). We thank Dr Thomas Lehner (NIMH). The work of the contributing groups was supported by
numerous grants from governmental and charitable bodies as well as philanthropic donation. Details are provided in
the supplementary material. Membership of the Wellcome Trust Case Control Consortium and of the Psychosis
Endophenotype International Consortium are provided in the Supplementary Text.
References
1. Saha S, Chant D, McGrath J. A systematic review of mortality in schizophrenia: is the differential
mortality gap worsening over time? Archives of General Psychiatry. 2007; 64:1123–31. [PubMed:
17909124]
2. World Health Organization. The Global Burden of Disease: 2004 Update. WHO Press; Geneva:
2008.
3. Knapp M, Mangalore R, Simon J. The global costs of schizophrenia. Schizophrenia Bulletin. 2004;
30:279–93. [PubMed: 15279046]
4. Lieberman JA, et al. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N
Engl J Med. 2005; 353:1209–23. [PubMed: 16172203]
5. Carlsson A, Lindqvist M. Effect of Chlorpromazine or Haloperidol on Formation of
3methoxytyramine and Normetanephrine in Mouse Brain. Acta Pharmacologica et Toxicologica.
1963; 20:140–4. [PubMed: 14060771]
6. van Rossum JM. The significance of dopamine-receptor blockade for the mechanism of action of
neuroleptic drugs. Archives Internationales de Pharmacodynamie et de Therapie. 1966; 160:492–4.
[PubMed: 5954044]
et al. Page 26
Nature. Author manuscript; available in PMC 2015 January 24.
 
E
u
r
o
p
e
 
P
M
C
 
F
u
n
d
e
r
s
 
A
u
t
h
o
r
 
M
a
n
u
s
c
r
i
p
t
s
 
E
u
r
o
p
e
 
P
M
C
 
F
u
n
d
e
r
s
 
A
u
t
h
o
r
 
M
a
n
u
s
c
r
i
p
t
s7. Lichtenstein P, et al. Recurrence risks for schizophrenia in a Swedish national cohort. Psychological
Medicine. 2006; 36:1417–26. [PubMed: 16863597]
8. Sullivan PF, Kendler KS, Neale MC. Schizophrenia as a complex trait: evidence from a meta-
analysis of twin studies. Archives of General Psychiatry. 2003; 60:1187–92. [PubMed: 14662550]
9. Sullivan PF, Daly MJ, O’Donovan M. Genetic architectures of psychiatric disorders: the emerging
picture and its implications. Nature Reviews Genetics. 2012; 13:537–51.
10. International Schizophrenia Consortium. Common polygenic variation contributes to risk of
schizophrenia and bipolar disorder. Nature. 2009; 460:748–52. [PubMed: 19571811]
11. Ripke S, et al. Genome-wide association analysis identifies 13 new risk loci for schizophrenia.
Nature Genetics. 2013; 45:1150–9. [PubMed: 23974872]
12. Ikeda M, et al. Genome-wide association study of schizophrenia in a Japanese population.
Biological Psychiatry. 2011; 69:472–8. [PubMed: 20832056]
13. Hamshere ML, et al. Genome-wide significant associations in schizophrenia to ITIH3/4,
CACNA1C and SDCCAG8, and extensive replication of associations reported by the
Schizophrenia PGC. Molecular Psychiatry. 2012
14. O’Donovan M, et al. Identification of novel schizophrenia loci by genome-wide association and
follow-up. Nature Genetics. 2008; 40:1053–5. [PubMed: 18677311]
15. Rietschel M, et al. Association between genetic variation in a region on chromosome 11 and
schizophrenia in large samples from Europe. Molecular Psychiatry. 2011
16. Schizophrenia Psychiatric Genome-Wide Association Study Consortium. Genome-wide
association study identifies five new schizophrenia loci. Nature Genetics. 2011; 43:969–76.
[PubMed: 21926974]
17. Irish Schizophrenia Genomics Consortium; Wellcome Trust Case Control Consortium. Genome-
wide association study implicates HLA-C*01:02 as a risk factor at the MHC locus in
schizophrenia. Biological Psychiatry. 2012
18. Shi J, et al. Common variants on chromosome 6p22.1 are associated with schizophrenia. Nature.
2009; 460:753–7. [PubMed: 19571809]
19. Shi Y, et al. Common variants on 8p12 and 1q24.2 confer risk of schizophrenia. Nature Genetics.
2011; 43:1224–7. [PubMed: 22037555]
20. Stefansson H, et al. Common variants conferring risk of schizophrenia. Nature. 2009; 460:744–7.
[PubMed: 19571808]
21. Steinberg S, et al. Common variants at VRK2 and TCF4 conferring risk of schizophrenia. Human
Molecular Genetics. 2011; 20:4076–81. [PubMed: 21791550]
22. Yue WH, et al. Genome-wide association study identifies a susceptibility locus for schizophrenia
in Han Chinese at 11p11. Nature Genetics. 2011; 43:1228–31. [PubMed: 22037552]
23. Lencz T, et al. Genome-wide association study implicates NDST3 in schizophrenia and bipolar
disorder. Nature Communications. 2013; 4:2739.
24. Psychiatric GWAS Consortium. A framework for interpreting genomewide association studies of
psychiatric disorders. Molecular Psychiatry. 2009; 14:10–7. [PubMed: 19002139]
25. Durbin RM, et al. A map of human genome variation from population-scale sequencing. Nature.
2010; 467:1061–73. [PubMed: 20981092]
26. Begum F, Ghosh D, Tseng GC, Feingold E. Comprehensive literature review and statistical
considerations for GWAS meta-analysis. Nucleic Acids Research. 2012; 40:3777–84. [PubMed:
22241776]
27. Lango Allen H, et al. Hundreds of variants clustered in genomic loci and biological pathways
affect human height. Nature. 2010; 467:832–8. [PubMed: 20881960]
28. Jostins L, et al. Host-microbe interactions have shaped the genetic architecture of inflammatory
bowel disease. Nature. 2012; 491:119–24. [PubMed: 23128233]
29. Yang J, et al. Genomic inflation factors under polygenic inheritance. European Journal of Human
Genetics. 2011; 19:807–12. [PubMed: 21407268]
30. Bulik-Sullivan, BK., et al. LD Score Regression Distinguishes Confounding from Polygenicity in
Genome-Wide Association Studies. 2014. http://dx.doi.org/10.1101/002931
et al. Page 27
Nature. Author manuscript; available in PMC 2015 January 24.
 
E
u
r
o
p
e
 
P
M
C
 
F
u
n
d
e
r
s
 
A
u
t
h
o
r
 
M
a
n
u
s
c
r
i
p
t
s
 
E
u
r
o
p
e
 
P
M
C
 
F
u
n
d
e
r
s
 
A
u
t
h
o
r
 
M
a
n
u
s
c
r
i
p
t
s31. Ferreira M, et al. Collaborative genome-wide association analysis of 10,596 individuals supports a
role for Ankyrin-G (ANK3) and the alpha-1C subunit of the L-type voltage-gated calcium channel
(CACNA1C) in bipolar disorder. Nature Genetics. 2008; 40:1056–8. [PubMed: 18711365]
32. Cross-Disorder Group of the Psychiatric Genomics Consortium. Identification of risk loci with
shared effects on five major psychiatric disorders: a genome-wide analysis. Lancet. 2013;
381:1371–9. [PubMed: 23453885]
33. Purcell SM, et al. A burden of ultra-rare disruptive mutations concentrated in synaptic gene
networks increases risk of schizophrenia. Nature. 2014; 506:185–190. [PubMed: 24463508]
34. Fromer M, et al. De novo mutations in schizophrenia identify pathogenic gene networks regulating
synaptic strength and overlap with autism and intellectual disability. Nature. 2014; 506:179–84.
[PubMed: 24463507]
35. Kirov G, et al. De novo CNV analysis implicates specific abnormalities of postsynaptic signalling
complexes in the pathogenesis of schizophrenia. Molecular Psychiatry. 2012; 17:142–53.
[PubMed: 22083728]
36. Wellcome Trust Case Control, C. et al. Bayesian refinement of association signals for 14 loci in 3
common diseases. Nature Genetics. 2012; 44:1294–301. [PubMed: 23104008]
37. Nicolae DL, et al. Trait-associated SNPs are more likely to be eQTLs: annotation to enhance
discovery from GWAS. PLoS Genetics. 2010; 6:e1000888. [PubMed: 20369019]
38. Maurano MT, et al. Systematic localization of common disease-associated variation in regulatory
DNA. Science. 2012; 237:1190–1195. [PubMed: 22955828]
39. Richards AL, et al. Schizophrenia susceptibility alleles are enriched for alleles that affect gene
expression in adult human brain. Molecular Psychiatry. 2012; 17:193–201. [PubMed: 21339752]
40. Wright F, et al. Heritability and genomics of gene expression in peripheral blood. Nature Genetics.
2014; 46:430–7. [PubMed: 24728292]
41. Doyle JP, et al. Application of a translational profiling approach for the comparative analysis of
CNS cell types. Cell. 2008; 135:749–62. [PubMed: 19013282]
42. Tkachev D, et al. Oligodendrocyte dysfunction in schizophrenia and bipolar disorder. Lancet.
2003; 362:798–805. [PubMed: 13678875]
43. Benros ME, Mortensen PB, Eaton WW. Autoimmune diseases and infections as risk factors for
schizophrenia. Annals of the New York Academy of Sciences. 2012; 1262:56–66. [PubMed:
22823436]
44. Holmans P, et al. Gene ontology analysis of GWA study data sets provides insights into the
biology of bipolar disorder. American Journal of Human Genetics. 2009; 85:13–24. [PubMed:
19539887]
45. Lee P, O’Dushlaine C, Thomas B, Purcell S. InRich: Interval-based enrichment analysis for
genome-wide association studies. Bioinformatics. 2012; 28:1797–9. [PubMed: 22513993]
46. Lee SH, Goddard ME, Wray NR, Visscher PM. A better coefficient of determination for genetic
profile analysis. Genetic Epidemiology. 2012; 36:214–24. [PubMed: 22714935]
47. Gottesman II, Gould TD. The endophenotype concept in psychiatry: etymology and strategic
intentions. American Journal of Psychiatry. 2003; 160:636–45. [PubMed: 12668349]
48. Insel T, et al. Research domain criteria (RDoC): toward a new classification framework for
research on mental disorders. American Journal of Psychiatry. 2010; 167:748–51. [PubMed:
20595427]
49. Howie B, Marchini J, Stephens M. Genotype imputation with thousands of genomes. G3. 2011;
1:457–70. [PubMed: 22384356]
50. Delaneau O, Marchini J, Zagury JF. A linear complexity phasing method for thousands of
genomes. Nature Methods. 2012; 9:179–81. [PubMed: 22138821]
51. Lips ES, et al. Functional gene group analysis identifies synaptic gene groups as risk factor for
schizophrenia. Molecular Psychiatry. 2012; 17:996–1006. [PubMed: 21931320]
52. Lewis BP, Burge CB, Bartel DP. Conserved seed pairing, often flanked by adenosines, indicates
that thousands of human genes are microRNA targets. Cell. 2005; 120:15–20. [PubMed:
15652477]
et al. Page 28
Nature. Author manuscript; available in PMC 2015 January 24.
 
E
u
r
o
p
e
 
P
M
C
 
F
u
n
d
e
r
s
 
A
u
t
h
o
r
 
M
a
n
u
s
c
r
i
p
t
s
 
E
u
r
o
p
e
 
P
M
C
 
F
u
n
d
e
r
s
 
A
u
t
h
o
r
 
M
a
n
u
s
c
r
i
p
t
sFigure 1. Manhattan plot
Manhattan plot of the discovery genome-wide association meta-analysis of 49 case control
samples (34,241 cases and 45,604 controls) and 3 family based association studies (1,235
parent affected-offspring trios). The x-axis is chromosomal position and the y-axis is the
significance of association (−log10(P)).The red line shows the genome-wide significance
level (5×10−8). SNPs in green are in LD with the index SNPs (diamonds) which represent
independent genome-wide significant associations.
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sFigure 2. Enrichment in enhancers
Cell and tissue type specific enhancers were identified using ChIP-seq datasets (H3K27ac
signal) from 56 cell line and tissue samples (Y-axis). We defined cell and tissue type
enhancers as the top 10% of enhancers with the highest ratio of reads in that cell or tissue
type divided by the total number of reads. Enrichment of credible causal associated SNPs
from the schizophrenia GWAS was compared with frequency matched sets of 1000
Genomes SNPs (Supplementary Text). The X-axis is the −log10(P) for enrichment. P-values
are uncorrected for the number of tissues/cells tested. A −log10(P) of roughly 3 can be
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sconsidered significant after Bonferroni correction. Descriptions of cell and tissue types at the
Roadmap Epigenome website (http://www.roadmapepigenomics.org).
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sFigure 3. Odds ratio by risk score profile
Odds ratio for schizophrenia by risk score profile (RPS) decile in the Sweden (Sw1-6),
Denmark (Aarhus), and Molecular Genetics of Schizophrenia studies (Supplementary text).
Risk alleles and weights were derived from ‘leave one out’ analyses in which those samples
were excluded from the GWAS meta-analysis (Supplementary text). The threshold for
selecting risk alleles was PT < 0.05. The RPS were converted to deciles (1=lowest,
10=highest RPS), and nine dummy variables created to contrast deciles 2-10 to decile 1 as
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sthe reference. Odds ratios and 95% confidence intervals (bars) were estimated using logistic
regression with PCs to control for population stratification.
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